Acne treatment methodologies

Cosmetic Formulation of Skin Care Products

Volumn , Issue , 2005, Pages 273-296

  Fernandez, Emmy M ^a   Zaenglein, Andrea L ^a   Thiboutot, Diane M ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123744585     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (130)

1. Smithard A, Glazebrook C, Williams H. Acne prevalence, knowledge about acne and psuchological morbidity in mid-adolescence: a community-based study. Br J Dermatol 2001; 145:274-279.
2. Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren: no longer a concern for dermatologists. BMJ 1989; 298:1217-1220.
3. Pearl A, Arroll B, Lello J, Birchal N. The impact of acne: a study of adolescents' attitudes, perception and knowledge. NZ Med J 1998; 1111:269-271.
4. Atkan S, Ozmen E, Sanli B. Anxiety, depression and nature of acne vulgaris in adolescents. Int J Dermatol 2000; 39:354-357.
5. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999; 41:577-580.
6. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. BMJ 1979; 166:1109-1110.
7. Scott-Levin. Acne. Physician Drug Diagn Audit 2000.
8. Baldwin HE. The interaction between acne vulgaris and the psyche. Cutis 2002; 70:133-139.
9. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999; 140:672-676.
10. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115:386.
11. Zaenglein AL, Thiboutot DM. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Acne Vulgaris. 1st ed. In: Dermatology, 1st ed, Vol. 1. New York: Elsevier, 2003:531-543.
12. Thiboutot D, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5A-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997; 136:166-171.
13. Thiboutot D, Knaggs H, Gilliland K, Lin G. Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology 1998; 196:38-12.
14. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metabol 1993; 76:524-528.
15. Downing D, Stewart M, Wertz P, Strauss J. Essential fatty acids and acne. J Am Acad Dermatol 1986; 14:221-225.
16. Guy R, Green M, Kealey T. Modeling of acne in vitro. J Invest Dermatol 1996; 106:176-182.
17. Sanders DA, Philpott MP, Nicolle FV, Kealey T. The isolation and maintenance of the human pilosebaceous unit. Br J Dermatol 1994; 131:166-176.
18. Harris HH. Sustainable rates of sebum secretion in acne patients and matched normal control subjects. J Am Acad Dermatol 1983; 8:200.
19. Kligman AM, Wheatley VR, Mills OH. Comedogenicity of human sebum. Arch Dermatol 1970; 102:267-275.
20. Pochi PE, Strauss JS. Sebaceous gland response in man to the administration of testosterone, Δ4-androstenedione, and dehydroisoandrosterone. J Invest Dermatol 1969; 52:32-36.
21. Thiboutot D, Gilliland K, Light J, Lookingbill D. Androgen metabolism in sebaceous glands from subjects with and without acne [see comments]. Arch Dermatol 1999; 135:1041-1045.
22. Lucky AW, Biro FM, Simbartl LA, Morrison JA, Sorg NW. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study [see comments]. J Pediatr 1997; 130:30-39.
23. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 15a-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995; 105:209-214.
24. Strauss J, Kligman A. Effect of cyclic progestin-estrogen therapy on sebum and acne in women. JAMA 1964; 190:815-819.
25. Thiboutot D. Regulation of human sebaceous glands. Dermatol Found 2003; 37:1-12.
26. Norris JFB, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol 1988; 118:651-659.
27. Leyden JJ. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975; 65:382.
28. Webster G, Indrisano J, Leyden JJ. Antibody titers to propionobacterium acnes cell wall carbohydrate in nodulocystic acne patients. J Invest Dermatol 1985; 84:496-500.
29. Webster GF. Complement activation in acne vulgaris. Consumption of complement by comedones. Infect Immuno 1979; 26:183.
30. Puhvel SM, Hoffman IK, Reisner RM. Delayed hypersensitivity of patients with acne vulgaris to corynebacterium acnes. J Invest Dermatol 1967; 49:154-158.
31. Webster G, Leyden JJ, Musson RA, Douglas SD. Susceptibility of propionobacterium acnes to killing and degradation by human neutrophils and monocytes in vitro. Infect Immuno 1985; 49:116-121.
32. Vowels B, Yang S, Leyden J. Induction of proinflammatory cytokines by a soluble factor of propionibactreium acnes: implications for chronic inflammatory acne. Infect Immun 1995; 63:3158-3165.
33. Kim J, Ochoa M, Krutzik S, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169:1535-1541.
34. Lee JK, Duong B, Ochoa M. Propionobacterium acnes induction of pro-inflammatory cytokines in polymorphonuclear cells occurs through toll-like receptor 2: the role of innate immune response in acne vulgaris. Abstr Soc Invest Dermatol 2002.
35. Fisher GF, Talwar HS, Xiao JH. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 1994; 269:20629-20635.
36. Fisher FJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. FASEB J 1996; 10:1002-1013.
37. Quigley JW, Bucks DA. Reduced skin irritation with tretinoin containing polyolprepolymer-2, a new topical tretinoin delivery system: a summary of preclinical and clinical investigations. J Am Acad Dermatol 1998; 38:S5-S10.
38. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998; 38:S17-S23.
39. Shalita A, Weiss J, Chalker D, et al. A comparison of the efficacy and safety of adapalene gel 0.01% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34.
40. Webster G, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001; 67:4-9.
41. Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis 2002; 69:12-19.
42. Bershad S, Kranjac Singer G, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002; 138:481-489.
43. Shapiro L, Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study [letter]. Lancet 1997; 350:1143-1144.
44. Jick S, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993; 341:1181-1182.
45. Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999; 37:273-287.
46. Menter A. Pharmocokinetics and safety of tazarotene. J Am Acad Dermatol 2000; 43:S31-S35.
47. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998; 139:8-11.
48. Hecker D, Worsley J, Yueh G. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 1999; 41:927-930.
49. Gfatter R, Hackl P, Braun F. Effects of soap and detergents on skin surface pH, stratum corneum hydration and fat content in infants. Dermatol 1997; 195:258-262.
50. Shehaded NH, Kligman AM. The effect of topical antibacterial agents on the bacterial flora of the axial. J Invest Dermatol 1963; 40:61-71.
51. Warren R, Ertel KD, Bartolo RG. The influence of hard water (calcium) and surfactants on irritant contact dermatitis. Contact Dermatitis 1996; 35:337-343.
52. Baranda L, Gonzalez-Amaro R, Torres-Alvarez B, Alvarez C, Ramirez V. Correlation between pH and irritant effect of cleansers marketed for dry skin. Int J Dermatol 2002; 41:494-499.
53. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther 2004; 17:26-34.
54. Draelos Z. Hydroxy acids for the treatment of aging skin. J Geriatr Dermatol 1997; 5:236.
55. Brackett W. The chemistry of salicylic acid. Cosmet Dermatol 1997; 10:5.
56. Davies MG, Marks R. Studies on the effect of salicylic acid on normal skin. Br J Dermatol 1976; 95:187-192.
57. Van Scott EJ, Yu RJ. Hyperkeratinization, corneocyte cohesion and alpha hydroxy acids. J Am Acad Dermatol 1984; 11:867-879.
58. Kligman AM. A comparative evaluation of a novel low-strength salicylic acid cream and glycolic acid products on human skin. Cosmet Dermatol 1997;11.
59. Baumann L. Cosmetic Dermatology: Principles and Practice. 1st ed. Hong Kong: McGraw-Hill, 2002.
60. BarandaL, Gonzalez-Amaro R, Torrer-Alvarez B, Alvarez C, Ramirez V. Correlation between pH and irritant effect of cleansers marketed for dry skin. Int J Dermato 2002; 41:494-499.
61. Eady E, Bojar R, Jones C, Cove J, Holland K, Cunliffe W. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996;134.
62. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 1998; 196:119-125.
63. Chalker DK, Shalita A, Smith JG, Swann RW. A double-blind study of the effectiveness of a 3% erythromcin and 5% benzoyl-peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9:933-936.
64. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37:590-595.
65. Leyden JJ. The evolving role of propionibacterium acnes in acne. Semin Cutan Med Surg 2001; 20:139-143 [Review] [26refs].
66. Nazzaro-Porro M, Passi S, Picardo M, Breathnach A, Clayton R, Zina G. Beneficial effect of 15% azelaic acid cream on acne vulgaris. Br J Dermatol 1983; 109:45-18.
67. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 2001; 15:51-55.
68. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline-a dose related phenomenon. Clin Exp Dermatol 1993; 18:425-427.
69. Bikowski J. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003; 2:222-228. Jul-Aug.
70. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139:459-464.
71. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheumatol 1999; 28:392-397.
72. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206:37-53.
73. Dickinson B, Altman R, Nielsen N, Sterling M. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001; 98:853-860.
74. Velicer C, Heckbert S, Lampe J. Antibiotic use in relation to the risk of breast cancer. J Am Med Assoc 2004; 291:827-835.
75. Eady EA. Bacterial resistance in acne. Dermatology 1998; 196:59-66.
76. Cooper AJ. Systematic review of propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169:259-261. Sep 7.
77. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology 2003; 206:56-67.
78. Jaussan V, Lemarchand-Bernaud T, Gomez F. Modifications of the gonadal function in the adult rat after fetal exposure to spironolactone. Biol Reprod 1985; 32:1051-1061.
79. Shaw J. Spironolactone in dermatologic therapy. J Am Acad Dermatol 1991; 24:236-243.
80. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43:498-502.
81. van Waygen R, van den Ende A. Experinece in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations. Exp Clin Endocrinol Diabetes 1995; 103:241-251.
82. Dodin S, Faure N, Cedrin I, et al. Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin Endocrinol 1995; 43:575-582.
83. Wysowski D, Freiman J, Tourtelot J, Horton M. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Int Med 1993; 118:860-864.
84. Vexiau P, Basoeyras M, Chaspoux C, Foin N, Allaert F. Acne in adult women: data from a national study on the relationship between type of acne and markers of clinical hyperandrogenism. Ann Dermatol Venereol 2002; 129:174-178.
85. Thiboutot D. Acne and rosacea: new and emerging therapies. Dermatol Clin 2000; 18:63-71.
86. Maloney M, Arbit D, Flack M, McLaughlin-Miley C, Sevilla C, Derman R. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Women's Health 2001; 1:124-131.
87. Beylot V, Faundes A, Alvarez F, Cochon L. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002; 65:63-74.
88. Pochi PE, Shalita AR, Strauss JS, et al. Report of the consensus conference on acne classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 1991; 24:495-500.
89. Cunliffe W, van de Kerkhof P, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194:351-357.
90. Tsukada M, Schroder M, Roos T, et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoic acid receptors. J Invest Dermatol 2000; 115:321-327.
91. Leyden JJ, McGinley KJ, Foglia AN. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol 1986; 86:390-393.
92. Cunliffe WJ, Layton AM. Oral isotretinoin: patient selection and management. J Dermatol Treat 1993; 4:S10-S15.
93. Strauss J, III, Rapini R, Shalita A. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10:490-496.
94. Layton AM, Knaggs H, Taylor H, Cuncliffe WJ. Isotretinoin for acne vulgaris-10 years later: a safe and successful treatment. Br J Dermatol 1993; 129:292-296.
95. Stainforth J, Layton A, Taylor J, Cunliffe W. Isotretinoin for the treatment of acne vulgaris: which factors predict the need for more than one course? Br J Dermatol 1993; 129:297-301.
96. Orfanos C, Zouboulis C. Oral retinoids in the treatment of seborrhea and acne. Dermatol 1998; 196:140-147.
97. Brecher AR, Orlow SJ. Oral retinoid therpay for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003; 49:171-182.
98. Hull PR, Demkiw-Bartel C. Isotretinoin use in acne: prospective evaluation of adverse events. J Cutan Med Surg 2000; 4:66-70.
99. McElwee NE, Schumacher MC, Johnson SC, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol 1991; 127:341-346.
100. Heudes AM, Laroche L. Muscular damage during isotretinoin treatment. Ann Dermatol Venereol 1998; 125:94-97.
101. Landau M, Mesterman R, Ophir J, Mevorah B, Alcalay J, Harel A. Clinical significance of markedly elevated creatinine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol 2001; 81:350-352.
102. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001; 45:S150-S157.
103. Quinn A, Singer S, Buncic J. Pediatric tetracycline-induced pseudotumor cerebri. J AAPOS 1999; 3:53-57.
104. Wysowski D, Pitts M, Beitz J. Depression and suicide in patients treated with isotretinoin. N Engl J Med 2001; 344:460.
105. Jick S, Kremers H, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide and attempted suicide. Arch Dermatol 2000; 136:1231-1236.
106. Chia C, Lane W, Chibnall J, Allen A, Siegfried E. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne. Arch Dermatol 2005; 141:557-560.
107. Hanson N, Leachman SA. Safety issues in isotretinoin therapy. Semin Cutan Med Surg 2001; 20:166-183.
108. Barth JH, MacDonald-Hull SP, Mark J, Jones RG, Cunliffe WJ. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993; 129:704-707.
109. Cunliffe WJ. Acne. London: Dunitz, 1989.
110. Melo TB. Uptake of protoporphyrin and violet light photodestruction of propionibacterium acnes. Z Naturforsch 1987; 42:123-128.
111. Lee WL, Shalita A, Poh-Fitzpatrick MB. Comparative studies of porhyria production in propionibacterium acnes and propionibacterium granulosum. J Bacteriol 1978; 133:811-815.
112. Arakane F, Ryu A, Hayashi C. Singlet oxygen (1 delta g) generation from coproporphyrin in propionibacterium acnes on irradiation. Biochem Biophys Res Commun 1996; 223:578-582.
113. Sigurdsson V, Knulst AC, van Weelden H. Phototherapyof acne vulgaris with visible light. Dermatol 1997; 194:256-260.
114. Kjelstad B, Johnsson A. An action spectrum for blue and near UV inactivation of propionibacterium acnes; with emphasis on a possible porphyrin photosensitization. Photochem Photobiol 1986; 43:67-70.
115. Suh DH, Kwon TE, Youn JI. Changes of comedonal cytokines and sebum secretion after UV irradiation in acne patients. Eur J Dermatol 2002; 12:139-144.
116. Mills OH, Kligman AM. UV phototherapy and photocemotherapy of acne vulgaris. Arch Dermatol 1978; 114:221-223.
117. Lassus A, Salo O, Forstrom L. Treatment of acne with selective UV-phototherapy (SUP): an open trial. Dermatol Monatsschr 1983; 169:376-379.
118. Meffert H, Kolzsch J, Laubstein B. Phototherapy of acne vulgaris with the "TuR" UV 10 body section irradiation unit. Dermatol Monatsschr 1986; 172:9-13.
119. Meffert H, Laubstein B, Kolzsch J. Phototherapy of acne vulgaris with the UVA irradiation instrument TBG 400. Dermatol Monatsschr 1986; 172:105-106.
120. van Weelden H, de Gruijl FR, van der Putte SC. The carcinogenic risks of modern tanning equipment: is UV-A safer than UV-B? Arch Dermatol Res 1988; 280:300-307.
121. Charakida A, Seaton E, Charakida M, Mouser P, Averginos A, Chu A. Phototherapy in the treatment of acne vulgaris. Am J Clin Dermatol 2004; 5:211-216.
122. Fien S, Ballard C, Nouri K. Multiple modalities to treat acne: a review of lights, lasers, and radiofrequency. Cosmet Dermatol 2004; 17:789-793.
123. Divaris DX, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol 1990; 136:891-897.
124. Ibbotson SH. Topical 5-aminolevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002; 146:178.
125. Seaton E, Charakida A, Mouser A. Pulsed dye laser treatment for inflammatory acne vulgaris: randomised controlled trial. Lancet 2003; 362:1347-1352.
126. Paithankar D, Ross V, Saleh B, Blair M, Graham B. Acne treatment with a 1450nm wavelength laser and cryogen spray cooling. Lasers Surg Med 2002; 31:106-114.
127. Friedman P, Jih M, Kimyai-Asadi A, Goldberg L. Treatment of inflammatory facial acne vulgaris with the 1450-nm diode laser: a pilot study. Dermatol Surg 2004; 30:147-151.
128. Lloyd J, Mirkov M. Selective photothermolysis of the sebaceous glands for acne treatment. Lasers Surg Med 2002; 31:115-120.
129. DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45:S176-S182.
130. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol 2001; 45:S188-S194.